alphaGalCer-RBD is a self-adjuvanting lipoprotein conjugate. alphaGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. alphaGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. alphaGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. alpha-Galactosylceramide (alphaGalCer) is a potent invariant natural killer T cell (iNKT) agonist[1]. RBD: receptor-binding domain
Molecular Weight:
1119.60
Formula:
C60H118N4O14
Target:
SARS-CoV
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted